Edimer Pharmaceuticals has announced that dosing has been completed for the first newborn enrolled in the Phase 2 Clinical Trial for EDI200. This marks an important milestone for Edimer and those affected by X-linked hyphidrotic ectodermal dysplasia (XLHED). EDI200 is a new drug being developed for XLHED. If approved, it will be the first drug to treat the symptoms of this rare genetic disorder. More importantly, it may be the first drug to improve the health and quality of life for boys with XLHED.